GlassScriptPhysician profile
Michelle H Bear
NPI 1508894494
$6,560.11
in general payments reported to CMS, 2019-2025
32 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $1,208 · 2021: $1,453 · 2022: $752 · 2023: $587 · 2024: $635 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,648.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $901.74 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $550.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $537.83 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $419.51 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $385.58 | 2021-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.40 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $252.23 | 2019-2022 | |
| Philips North America LLC | $171.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $166.13 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $165.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $137.71 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $133.47 | 2021 | |
| Amgen INC. | $129.11 | 2019-2022 | |
| Exact Sciences Corporation | $100.21 | 2024-2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $84.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.07 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $75.36 | 2022-2024 | Rexulti |
| Allergan, INC. | $50.00 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $43.64 | 2019-2020 | |
| Abbott Laboratories | $39.49 | 2019-2021 | |
| Eisai INC. | $38.77 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $29.89 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.11 | 2022 | |
| Viiv Healthcare Company | $17.63 | 2025 | Apretude |
| Idorsia Pharmaceuticals US INC | $16.93 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.47 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.45 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Seqirus USA INC | $12.93 | 2019 | |
| Circassia INC. | $12.78 | 2019 | |
| Amarin Pharma, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.